This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma

NCT07121946 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

42

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-Hodgkin Lymphoma Refractory/ Relapsed
DLBCL - Diffuse Large B Cell Lymphoma
Mantle Cell Lymphoma (MCL)
Follicular Lymphoma ( FL)
Marginal Zone Lymphoma (MZL)

Interventions

BIOLOGICAL: LTZ-301
BIOLOGICAL: LTZ-301
BIOLOGICAL: LTZ-301

Sponsor

LTZ Therapeutics, Inc.